Navigation Links
Wyeth Announces Executive Promotions

- Leadership in Place for CEO Transition on January 1 -

MADISON, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced senior management promotions of several executives who have been key contributors to Wyeth's success over the past several years.

"As I prepare for the role of Chief Executive Officer in January, I am pleased to have these experienced executives in place to build on Wyeth's strong foundation of success established by Bob Essner," says Bernard Poussot, President and Chief Operating Officer, Wyeth. "As several successful leaders retire as planned from key positions, I am delighted that we have been able to develop and then promote talented successors from within our organization. This enables us to continue to build strength through core brands, invest in R&D, bring new products to market and manage costs -- all key elements of Wyeth's growth strategy."

Joseph M. Mahady, President, Wyeth Pharmaceuticals

Joseph M. Mahady, 54, was elected to the position of President, Wyeth Pharmaceuticals and Senior Vice President, Wyeth, effective January 1, 2008. Mr. Mahady joined the Company in 1979 as a pharmacist in Regulatory Affairs. Following his progression through numerous management positions, he was appointed President, U.S. for Wyeth Pharmaceuticals in 1995. In 2003, Mr. Mahady assumed responsibility for all global business units. In 2005, he assumed responsibility for Latin America, and in February 2007 he was appointed President -- Global Business, Wyeth Pharmaceuticals with responsibility for all worldwide commercial businesses.

"Under Joe's leadership, our commercial success in the pharmaceuticals business has been key to Wyeth's continuing revenue growth," says Mr. Poussot. "It is the combination of his leadership, knowledge and passion for our business that makes him the ideal person to lead our pharmaceutical organization in a challenging environment."

Mr. Mahady earned his pharmacy degree in 1977 from St. John's University College of Pharmacy and his M.B.A. from Fairleigh Dickinson University in 1986.

Richard R. DeLuca, President, Fort Dodge Animal Health

Richard R. DeLuca, 45, was elected to the position of President, Fort Dodge Animal Health, effective January 1, 2008. Mr. DeLuca succeeds Mr. E. Thomas Corcoran, 60, who is retiring after serving as President of the Company's animal health division for 23 years.

Mr. DeLuca, currently Chief Operating Officer at Fort Dodge Animal Health, has been with Wyeth since 1988. He has held positions of increasing responsibility, including Executive Vice President Finance/Administration and Chief Financial Officer at Fort Dodge; Vice President, Finance, Wyeth Research; and Vice President, Finance, Wyeth Pharmaceuticals. He holds a bachelor's degree in business administration and accounting from Widener University.

"Rick is an accomplished leader who has made significant contributions to the growth and success of our animal health business. He brings a strong mix of leadership, operational experience and business knowledge to this position," says Mr. Poussot.

Mr. Corcoran joined Fort Dodge Animal Health in 1985 as Division President. He was promoted to Vice President of Wyeth in 1993 with responsibility for the animal health and specialty pharmaceutical businesses. He is immediate past Chairman of The Animal Health Institute's Executive Committee and of its Board of Directors.

Mr. Corcoran recently was named the recipient of two prestigious awards for his dedication to the animal health industry. He was honored with the 2007 Animal Pharm Lifetime Achievement Award, and then received the 2007 Leadership Award from Banfield, The Pet Hospital(R). Both awards are given to an individual who makes significant changes and improvements to the animal health industry and profession.

"Tom has taken Fort Dodge from a small biologicals company to a growing organization recognized today as a global leader in the animal health industry that sells products in more than 100 countries," says Mr. Poussot. "His dedication to innovative animal health research has helped develop important pharmaceutical products and vaccines."

Cavan M. Redmond, President, Wyeth Consumer Healthcare

Cavan M. Redmond, 46, was promoted to the position of President, Wyeth Consumer Healthcare effective December 1, 2007. Mr. Redmond will be responsible for the division's global operations. The Company also announced that Douglas A. Rogers, 47, has been named to the position of President, U.S. and Global New Business, Wyeth Consumer Healthcare.

Mr. Redmond has been serving as Executive Vice President and General Manager of the BioPharma business unit of Wyeth Pharmaceuticals. He also has held positions of increasing responsibility in the commercial and R&D organizations. Prior to joining Wyeth Pharmaceuticals, Mr. Redmond worked at Sandoz both in the United States and in Switzerland. He earned a bachelor's degree in political science from the University of Maryland and a master's degree in administration from The Johns Hopkins University. He also completed a post-graduate fellowship in organizational change management.

Most recently, Mr. Rogers served as President, Wyeth Consumer Healthcare, and prior to that, he served as President, Wyeth Consumer Healthcare, U.S. He joined Wyeth in November 1994 with the acquisition of American Cyanamid, where he was Vice President of Marketing for Lederle Consumer Health. Before that, he held various sales and marketing positions for Lederle Pharmaceuticals, Lederle Consumer Health, American Home Foods and Wyeth Consumer Healthcare. He holds a bachelor's degree in journalism and an M.B.A., both from Lehigh University.

"Under Cavan's leadership, Wyeth has become the third largest biotech company in the world. We know he'll bring the same formula for success to our consumer brands," says Mr. Poussot. "In addition, Doug's marketing and commercial skills, coupled with his in-depth knowledge, energy and experience, will serve as a tremendous advantage for the division."

Denise Peppard, Senior Vice President Human Resources, Wyeth

Denise Peppard, 50, was elected to the position of Senior Vice President Human Resources, Wyeth, effective January 1, 2008. Ms. Peppard succeeds Rene R. Lewin, 61, who is retiring after serving as the head of Wyeth Human Resources since 1994.

Ms. Peppard, currently Vice President, Corporate Human Resources, has been with Wyeth since 1999. She has held positions of increasing responsibility, including Senior Vice President of Human Resources for Wyeth Pharmaceuticals and Vice President of Human Resources for the North America pharmaceutical sales and marketing business.

"Denise has provided outstanding leadership to Wyeth's pharmaceutical organization," says Mr. Poussot. "She focused her efforts on facilitating positive change in our pharmaceutical business and has redefined the role of human resources through an increased business orientation. She will bring similar innovation to her new role."

Prior to joining the Company, Ms. Peppard worked as Senior Director, Organization Development and Training at Parke-Davis in Ann Arbor, Michigan and as Vice President of Human Resources at a biotechnology start-up firm.

Ms. Peppard received a bachelor's degree in business administration and accounting, as well as an M.B.A. with a dual concentration in organizational behavior and finance, from the University of Michigan.

Mr. Lewin joined Wyeth in 1994 as Vice President, Human Resources and was promoted to Senior Vice President in 2004. During his previous employment at Eli Lilly and Company, he held a variety of management positions, including President and General Manager, Eli Lilly Canada; Executive Director, Corporate Affairs; and Executive Director, Human Resources.

"Rene has served as the architect of Wyeth's performance-based rewards culture and has had a tremendous impact on our success," says Mr. Poussot. "Under his leadership, we have implemented innovative human resources strategies that recognized the changing needs of our workforce and our global business. These have included continuous process improvements, a robust global talent strategy and leadership development initiatives that are considered state-of-the-art in our industry. Through the strategic programs he has created, it is to Rene's credit that we have been able to recruit, retain and develop top talent as exemplified by the executive transitions being announced today."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
2. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care
3. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
4. Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
5. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
6. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
7. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
10. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
11. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology: